Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FQ61T
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,273
Award facts
- Contract value 100% obligated
- $10,273.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector syringes. The contract, issued on June 2, 2025, with an ultimate completion date of June 24, 2025, represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499,999,999 and extending through November 2026. DLA's pharmaceutical supply programs ensure critical medications and medical supplies reach Department of Defense healthcare facilities and military personnel worldwide.
This delivery order falls within DMS Pharmaceutical Group's established role as a key supplier in the federal pharmaceutical supply chain under the SPE2DB program, through which DLA procures an extensive portfolio of branded and generic prescription drugs, biologics, and medical consumables. Xolair (omalizumab) is a biologic immunosuppressant used in treating moderate-to-severe allergic asthma and chronic idiopathic urticaria, making this procurement representative of the specialized pharmaceutical products DMS Pharmaceutical Group regularly delivers to military health facilities. The award carries no set-aside designation, demonstrating the contractor's competitive positioning within the open federal marketplace despite its small business status.
Quick answers
Who was awarded contract SPE2DB25FQ61T?
SPE2DB25FQ61T was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 2, 2025.
How much is contract SPE2DB25FQ61T worth?
The government has obligated $10,273 on SPE2DB25FQ61T.
Is contract SPE2DB25FQ61T an order under another contract?
Yes. SPE2DB25FQ61T is a delivery order under SPE2DB20D9226, an indefinite delivery contract.
Was contract SPE2DB25FQ61T competed?
The extent of competition for SPE2DB25FQ61T was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award